PDCD1 and melanoma: We further tested the predictive performance of the ImmuneRiskScore on the efficacy of ICB treatment in four public RNA-seq datasets (melanoma: HugoW_Cell_anti.PD-L1/Gide_CancerCell_anti.PD-1; RCC: Miao_Science_anti.PD-1/Miao_Science_multiTreat).